新天地药业股份有限公司 公司已就上述变更会计师事务所的事项与毕马威华振会计师事务所（特殊普 一、2023 年年审会计师事务所基本情况 （一）会计师事务所基本情况 致同会计师事务所（特殊普通合伙）(以下简称"致同"）前身是成立于 1981 年的北京会计师事务所，1986 年 6 月脱钩改制并与京都会计师事务所合并，2011 年经北京市财政局批准转制为特殊普通合伙，更名为致同会计师事务所（特殊普 通合伙）。注册地址：北京市朝阳区建国门外大街 22 号赛特广场五层。首席合 伙人： 李惠琦。截至 2023 年末，合伙人 225 名，注册会计师 1,364 名，签 署过证券服务业务审计报告的注册会计师超过 400 人。 （二）聘任会计师事务所履行的程序 公司于 2023 年 8 月 22 日召开了第五届董事会审计委员会 2023 年度第三次 会议，审议通过了《关于变更会计师事务所的议案》。 公司于 2023 年 8 月 23 日召开第五届董事会第十四次会议和第五届监事会第十一次会议，审议通过了 《关于变更会计师事务所的议案》，同意聘任致同为公司 2023 年度审计机构， 聘期为一年。同时，公司董事会提请股东大会授权公司 ...

证券代码：301277 证券简称：新天地 公告编号：2024-026 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2024 年第一季度报告》。 表决结果：3票同意，0票反对，0票弃权。该议案表决通过。 新天地药业股份有限公司 第六届监事会第一次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 新天地药业股份有限公司（以下简称"公司"）第六届监事会第一次会 议（以下简称"本次会议"）于公司2023年年度股东大会选举产生第六届监 事会非职工代表监事，以及2024年3月23日职工代表大会选举产生的第六届监 事会职工代表监事，共同组成了公司第六届监事会后，经全体监事同意豁免 会议通知时间要求，以口头等方式向全体监事送达。本次会议于2024年4月23 日在公司会议室以现场方式召开。本次会议应出席监事3人，实际出席监事3人， 由全体监事推选监事胥和平先生主持会议。本次会议的召集、召开方式和程序 符合《中华人民共和国公司法》（以下简称"《公司法》"）等法律、法规和 《公司章程》的规定。 经与会监事充分讨论，本次会议审议通过议案 ...

证券代码：301277 证券简称：新天地 公告编号：2024-022 新天地药业股份有限公司 2023年年度股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 1. 本次股东大会无否决议案的情形。 2. 本次股东大会未涉及变更以往股东大会已通过决议的情形。 （一）会议召开情况 1.会议召开时间 （1）现场会议时间：2024年4月23日（星期二）下午14:30 （2）网络投票时间：2024年4月23日，其中，通过深圳证券交易所交易 系统进行网络投票的具体时间为2024年4月23日9：15—9：25，9：30—11： 30 和 13：00—15：00；通过深圳证券交易所互联网投票系统投票的具体时 间为2024年4月23日9：15—15：00期间的任意时间。 2. 公司董事、监事、高级管理人员及北京市天元律师事务所见证律师以 现场结合通讯的方式列席本次会议。 本次股东大会按照会议议程，采用现场投票与网络投票相结合的方式进 行表决，审议通过了如下议案： 2.会议召开地点：河南省长葛市魏武路南段东侧新天地药业股份有限公 司办公楼二楼会议室。 3.会议召集 ...

北京市天元律师事务所 关于新天地药业股份有限公司 2023 年年度股东大会的法律意见 京天股字（2024）第 126 号 致：新天地药业股份有限公司 新天地药业股份有限公司（以下简称"公司"）2023 年年度股东大会（以下简 称"本次股东大会"）采取现场投票与网络投票相结合的方式，现场会议于 2024 年 4 月 23 日在河南省长葛市魏武路南段东侧新天地药业股份有限公司会议室召开。 北京市天元律师事务所（以下简称"本所"）接受公司聘任，指派本所律师参加本次 股东大会现场会议，并根据《中华人民共和国公司法》《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股东大会规则》（以下简称"《股东大会 规则》"）以及《新天地药业股份有限公司章程》（以下简称"《公司章程》"）等 有关规定，就本次股东大会的召集、召开程序、出席现场会议人员的资格、召集人 资格、会议表决程序及表决结果等事项出具本法律意见。 为出具本法律意见，本所律师审查了《新天地药业股份有限公司第五届董事会 第十八次会议决议公告》《新天地药业股份有限公司第五届监事会第十四次会议决 议公告》《新天地药业股份有限公司关于召开 2023 年年度股东大 ...

Financial Performance - The company's revenue for Q1 2024 was ¥184,582,736.49, representing a 6.98% increase compared to ¥172,543,768.63 in the same period last year[5] - Net profit attributable to shareholders was ¥55,918,069.57, up 19.69% from ¥46,718,321.32 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥52,269,113.77, reflecting a 22.37% increase from ¥42,712,549.58 in the previous year[5] - Basic and diluted earnings per share increased to ¥0.28, a rise of 21.74% from ¥0.23 in the previous year[5] - Operating profit for the period reached CNY 60,490,595.72, up from CNY 53,167,681.76, reflecting a growth of 13.0%[18] - Net profit attributable to shareholders of the parent company was CNY 55,918,069.57, compared to CNY 46,718,321.32 in the previous year, marking an increase of 19.4%[19] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.28, up from CNY 0.23 in Q1 2023, representing a growth of 21.7%[19] Cash Flow - The company's cash flow from operating activities decreased by 48.55%, amounting to ¥19,090,039.25 compared to ¥37,102,568.29 in the same quarter last year[5] - Cash flow from operating activities generated a net amount of CNY 19,090,039.25, down from CNY 37,102,568.29 in the same period last year[20] - The net cash flow from investment activities was -48,197,311.37 CNY, a decrease from 105,965,472.44 CNY in the previous year[22] - The net cash flow from financing activities was -442,776.82 CNY, compared to -1,200,015.00 CNY in the previous year[22] - The net increase in cash and cash equivalents was -29,488,684.55 CNY, a significant decrease from 141,830,721.77 CNY in the previous year[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,725,566,402.02, a 7.21% increase from ¥1,609,505,725.79 at the end of the previous year[5] - Total current assets amount to ¥1,242,798,050.46, an increase from ¥1,156,650,004.07 at the beginning of the period[13] - Total current liabilities increased to ¥175,238,104.96 from ¥139,472,291.37, representing a growth of approximately 25.7%[14] - Total liabilities amounted to CNY 219,950,094.99, an increase from CNY 160,016,759.10 in the previous year[18] - Total equity attributable to shareholders of the parent company was CNY 1,504,675,298.87, up from CNY 1,448,017,461.58, indicating a growth of 3.9%[18] Research and Development - The company's R&D expenses rose by 49.59% to ¥11,990,186.88, driven by increased investment in raw material and formulation projects[9] - Research and development expenses increased to CNY 11,990,186.88, compared to CNY 8,015,163.95 in Q1 2023, reflecting a rise of 49.5%[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 16,251[11] - The largest shareholder, Henan Shuangjie Industrial Co., Ltd., holds 126,447,750 shares, accounting for 63.21% of total shares[11] Other Financial Metrics - The company reported a significant increase in receivables, with notes receivable rising by 74.71% to ¥120,531,455.84 due to an increase in bank acceptance bills received[9] - Deferred income increased by 246.33% to ¥34,777,350.00, primarily due to an increase in government subsidies related to assets[9] - The company reported a decrease in total operating costs to CNY 127,021,147.68 from CNY 127,637,155.52, a reduction of 0.5%[17] - Other income for the period was CNY 1,063,311.42, significantly higher than CNY 70,970.00 in the previous year, showing an increase of 1393.5%[18] - The company did not undergo an audit for the first quarter report[23]

证券代码：301277 证券简称：新天地 公告编号：2024-021 新天地药业股份有限公司 关于获得化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 2024年4月2日，新天地药业股份有限公司(以下简称"公司")收到国家药 品监督管理局核准签发的艾司奥美拉唑镁原料药《化学原料药上市申请批准通 知书》,现将相关情况公告如下： | 化学原料药名称 | 通用名称：艾司奥美拉唑镁 | | --- | --- | | | 英文名/拉丁名：Esomeprazolum magnesicum trihydricum | | 通知书编号 | 2024YS00271 | | 登记号 | Y20220000624 | | 有效期 | 24个月 | | 包装规格 | 1kg/桶、2kg/桶、3kg/桶、5kg/桶、10kg/桶、15kg/桶、 | | | 25kg/桶 | | 申请事项 | 境内生产化学原料药上市申请 | | 审批结论 | 根据《中华人民共和国药品管理法》，经审查，本品符 | | | 合仿制药审批的有关规定，批准生产本品。质量标准 ...

证券代码：301277 证券简称：新天地 公告编号：2024-020 新天地药业股份有限公司 关于召开2023年年度股东大会通知的更正公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 新天地药业股份有限公司（以下简称"公司"）于2024年3月26日在巨潮 资讯网（www.cninfo.com.cn)发布了《关于召开2023年年度股东大会的通知》 （公告编号：2024-018）（以下简称"原通知"）。为对原通知部分内容进 一步细化描述，以避免投资者产生误解，对原通知中"二、会议审议事项" 及"附件二：授权委托书"的相关内容予以补充更正。 本补充更正不涉及原通知的实质性变更，敬请投资者关注。具体内容如 下： 补充更正前： 二、会议审议事项 1.本次股东大会提案名称及编码表 | | | 备注 该列打 | | --- | --- | --- | | 提案编码 | 提案名称 | 勾的栏 | | | | 目可以 | | | | 投票 | | 100 | 总议案：除累积投票提案外的所有提案 | √ | | 非累积投 | | | | 票提案 | | | | 1.00 | ...

Financial Performance - The company's operating revenue for 2023 was CNY 651,436,758.68, representing a 3.84% increase compared to CNY 627,364,047.52 in 2022[23]. - The net profit attributable to shareholders for 2023 was CNY 158,979,232.75, a 20.16% increase from CNY 132,304,592.95 in 2022[23]. - The net cash flow from operating activities surged by 213.19% to CNY 259,459,970.22 in 2023, compared to CNY 82,845,438.18 in 2022[23]. - Total revenue for 2023 reached ¥651,436,758.68, representing a year-on-year increase of 3.84% compared to ¥627,364,047.52 in 2022[62]. - Revenue from pharmaceutical intermediates was ¥643,848,065.01, accounting for 98.84% of total revenue, with a year-on-year growth of 3.64%[62]. - The company reported a total of CNY 14,822,675.02 in non-recurring gains for 2023, compared to CNY 2,599,812.76 in 2022[29]. - The company reported a total revenue of 9999 million for the year 2022, indicating a stable performance[187]. - The company reported a significant increase in revenue for the fiscal year 2022, reaching 9999 million, reflecting a strong performance compared to the previous year[189]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 4 RMB per 10 shares to all shareholders, based on a total of 200,040,000 shares[3]. - The profit distribution plan for 2022 was approved, with a cash dividend of 5 RMB per 10 shares (including tax) and a capital reserve conversion of 5 shares for every 10 shares held[150]. - The company reported a profit distribution plan of 4 RMB per 10 shares and a capital reserve conversion of 4 shares per 10 shares[151]. - The company aims to enhance investor returns through its clear profit distribution and capital reserve conversion plans[151]. - The company plans to prioritize cash dividends, distributing at least 10% of the distributable profits in the absence of major investment plans or significant cash expenditures[185]. - In the next three years, the company aims to maintain a minimum cash dividend ratio of 20% due to its growth stage and significant capital expenditure plans[186]. - The company will ensure that cash dividends are distributed within two months after the shareholder meeting decision[186]. Research and Development - The company has established long-term collaborations with universities and research institutions to strengthen its R&D capabilities[42]. - The company is committed to innovation, with a focus on developing new drugs and improving existing products in response to market demands[39]. - The company has established R&D platforms in Beijing and Zhengzhou to accelerate technological innovation and project development[47]. - R&D expenses increased by 73.19% to ¥51,962,017.16, driven by higher investments in raw materials and formulations[69]. - The number of R&D personnel increased to 240 in 2023, up 57.89% from 152 in 2022, with R&D personnel accounting for 23.76% of the total workforce[72]. - R&D investment reached ¥51,962,017.16 in 2023, representing 7.98% of operating revenue, a significant increase from 4.78% in 2022[73]. - The company is investing in R&D, with a budget increase of 25% to enhance product innovation and technology development[132]. Market and Sales Strategy - The company is expanding its market presence through both direct sales and partnerships with trading companies for international clients[46]. - Domestic sales contributed ¥641,158,923.48, up 4.89% year-on-year, while international sales dropped by 36.15% to ¥10,277,835.20[62]. - The company is actively expanding its integrated development strategy of intermediates and raw materials, which is expected to enhance product value and drive revenue growth[50]. - The company is considering strategic acquisitions to bolster its product portfolio, with a target of completing at least one acquisition by the end of the fiscal year[132]. - The company plans to enhance its digital marketing strategy, allocating an additional 10% of its budget to online advertising[132]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2025[134]. Compliance and Governance - The company emphasizes that forward-looking statements regarding operational plans and future strategies do not constitute substantial commitments or profit forecasts to investors[3]. - The company maintains compliance with corporate governance regulations and has a structured board with independent directors to ensure sound decision-making[109]. - The company has established a transparent and effective performance evaluation and incentive mechanism for its management team[112]. - The company has not reported any significant changes in its board of directors or senior management apart from the aforementioned appointments and resignations[124]. - The company will ensure that any commitments made are in compliance with the latest regulations from the China Securities Regulatory Commission[184]. - The company has established strict compliance measures regarding the management of raised funds and related party transactions to protect shareholder interests[189]. Environmental and Social Responsibility - The company has established a clean production leadership group and invested continuously in environmental facilities to ensure compliance with waste discharge standards[100]. - The company has received the "Waste-Free Factory" honor from Xuchang City, reinforcing its commitment to waste management and resource utilization[166]. - The company has implemented a comprehensive environmental monitoring plan, including automatic and manual monitoring methods, to ensure compliance with pollution discharge standards[168]. - The company has committed to enhancing its core competitiveness through innovation and product transformation in response to market-oriented strategies[100]. - The company has actively participated in social responsibility initiatives, donating a total of 144,000 yuan to various charitable activities in 2023[176]. Risk Management - The company has detailed potential risk factors and countermeasures in its report, urging investors to be aware of investment risks[3]. - The company faces risks related to its core product, L-α-hydroxyphenylglycine, which contributes over 80% to its main business revenue, making it vulnerable to demand fluctuations[99]. - The company is facing potential risks from national healthcare policies that may pressure drug prices downward, impacting future profitability[100]. - The company emphasizes a dual prevention system for safety management and has implemented a PDCA cycle management model to mitigate safety risks[100]. Investment and Fundraising - The company raised a total of ¥900,720,000 through its initial public offering, with a net amount of ¥815,565,800 after deducting issuance costs[85]. - The company plans to invest ¥100,000,000 of its excess raised funds into the construction of an intelligent specialty raw material pharmaceutical supply chain project[89]. - The total investment amount for the reporting period reached ¥3,789,714,975.79, a significant increase of 389.41% compared to ¥774,342,722.37 in the same period last year[81]. - The company has not engaged in any securities or derivative investments during the reporting period[82][83]. Employee and Management - The company has a total of 240 technical personnel, accounting for 23.76% of its total workforce, indicating a strong focus on R&D capabilities[54]. - The management team has over ten years of experience in the industry, providing deep insights into market dynamics and enhancing strategic decision-making[59]. - The company has established a competitive salary and benefits system to enhance employee motivation and performance, aligning with the principles of fairness and contribution-based distribution[148].

关于召开2023年年度股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 新天地药业股份有限公司（以下简称"公司"）根据2024年3月23日召开 的第五届董事会第十八次会议决议，定于2024年4月23日下午14:30在公司召 开2023年年度股东大会。现将召开本次会议有关事宜通知如下： 1.股东大会届次：2023年年度股东大会 证券代码：301277 证券简称：新天地 公告编号：2024-018 新天地药业股份有限公司 2.股东大会的召集人：公司董事会 3.会议召开的合法、合规性：经公司第五届董事会第十八次会议审议通过， 决定召开2023年度股东大会，召集程序符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 4.会议召开的日期、时间： （1）现场会议召开时间：2024年4月23日下午14:30 7.出席对象： （1）截止股权登记日下午收市时在中国证券登记结算有限责任公司深圳分 公司登记在册的公司全体股东均有权出席股东大会，并可以以书面形式委托代 理人出席会议和参加表决，该股东代理人不必是本公司股东（授权委托书式样 见附件二）； ...

证券代码：301277 证券简称：新天地 公告编号：2024-008 新天地药业股份有限公司 第五届董事会第十八次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 新天地药业股份有限公司（以下简称"公司"）第五届董事会第十八次会议 （以下简称"本次会议"）于2024年3月23日上午9点在公司会议室以现场方式召 开。本次会议应出席董事9人，亲自出席9人，委托出席0人。本次会议由董事长 谢建中先生主持，公司监事及高级管理人员列席了会议。 本次会议的召集、召开方式和程序符合《中华人民共和国公司法》（以下简 称"《公司法》"）等法律、法规和《公司章程》的规定。 经与会董事充分讨论，本次会议审议通过议案如下： （一）审议通过《关于<2023年年度报告>及其摘要的议案》 公司已依照中国证券监督管理委员会《公开发行证券的公司信息披露内容与 格式准则第2号——年度报告的内容与格式》之规定编制了公司《2023年年度报 告》及其摘要。 公司董事会审计委员会审议并通过该议案。 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2023 年年 ...